çéèèªé žãã¢ã¬ã«ã®ãŒãæå¶ããäœçšæ©æ§ã解æ
ïœã¢ã¬ã«ã®ãŒã«å¯Ÿããé£ç©ç¹ç¶ã®æå¹æ§ãååã¬ãã«ã§å®èšŒïœ
ç 究ã®èŠæšãšãã€ã³ã
1.è žå 现èã«ãã£ãŠé£ç©ç¹ç¶ããçæãããçéèèªé žã¯ãå ç«èª¿ç¯æ©èœãæããã¢ã¬ã«ã®
ããŒåå¿ãæå¶ããããšãç¥ãããŠããŸããããã®äœçšæ©æ§ã«ã€ããŠã¯æªè§£æã®ãŸãŸã§ã
ããã
2.çéèèªé žããã¹ã现èãä»ããŠã¢ã¬ã«ã®ãŒæå¶äœçšãçºæ®ããéã®ååæ©æ§ããããŠ
ãã¹ã»çŽ°èã»éºäŒåã¬ãã«ã®è§£æãçµã¿åãããããšã§è§£æããŸããã
3.ããŠã¹ãçšããå®éšãããçéèèªé žããã³ãã€ã¢ã·ã³ãã¢ããã£ã©ãã·ãŒãæ¹åããã
ããšãNSAIDsããã®æ¹åå¹æãé»å®³ããããšãæããã«ããŸããã
4.æ¬ç 究ã¯ãç§ãã¡ãæ¥åžžçã«å£ã«ããé£äºã®å 容ãå¥åº·ã«åœ±é¿ãåãŒãããšããç§åŠçæ ¹
ãæ ããã£ãŠç€ºããéèŠãªææã§ãé£äºå 容ã®èŠçŽããææ¡ã«ãã€ãªãããšæåŸ ãããŸãã
ç 究ã®æŠèŠ
ãæ±äº¬çç§å€§åŠå é²å·¥åŠéšçåœã·ã¹ãã å·¥åŠç§ã®è¥¿å±±åæ¥ææãã®ç 究ã°ã«ãŒãã¯ãçéèèªé žã瀺ãã¢ã¬ã«ã®ãŒæå¶äœçšã«ã€ããŠãããŠã¹ã»çŽ°èã»éºäŒåã¬ãã«ã®è§£æãçµã¿åãããããšã«ããããã®è©³çŽ°ãªäœçšæ©æ§ã®è§£æã«æåããŸããã
æ¬ç 究ã«ãããçéèèªé žããã³é£ç©ç¹ç¶ãæã€æã¢ã¬ã«ã®ãŒäœçšã®èæ¯ã«ããã¡ã«ããºã ãæããã«ãªããŸããã
ãçéèèªé ž(*1)ã¯ãäž»ã«é£ç©ç¹ç¶ãè žå 现èã«ãã£ãŠä»£è¬ãããéã«çæãããç©è³ªã§ãé ªé žãåèé žãããããªã³é žãé ¢é žãªã©ã®ç·ç§°ã§ãã
è¿å¹Žã®ç 究ãããçéèèªé žã«ã¯ãå ç«çŽ°èã§ãããã¹ã现è(*2)ã®ã¯ãããã調ç¯ããã¢ã¬ã«ã®ãŒåå¿ãæå¶ããæ©èœãããããšãæããã«ãªããŸãããããããªãããçéèèªé žããã¹ã现èã«äœçšãããã®ååæ©æ§ã«ã€ããŠã¯æªè§£æã®ãŸãŸã§ããã
ã西山ææãã®ç 究ã®çµæãçéèèªé žãçµå£æåããããŠã¹ã§ã¯ãã¢ããã£ã©ãã·ãŒ(匷ãã¢ã¬ã«ã®ãŒåå¿)ãææã«æ¹åãããããšããŸããçéèèªé žãšãšãã«å¹é€ãããã¹ã现èã§ã¯ãIgEæäœ(*3)ã«ããèªå°ããã掻æ§åãææã«æå¶ãããããšãæããã«ãªããŸããã
ããã«ãåçš®é»å®³å€ãéºäŒåæè¡ãçšãã解æãããçéèèªé žã«ãããã¹ã现è掻æ§åæå¶ã«é¢äžãã2ã€ã®çµè·¯ãããªãã¡ãGã¿ã³ãã¯è³ªå ±åœ¹åå容äœ(*4)GPR109Aãä»ããçµè·¯ããšããå ç«é¢é£éºäŒåã®ãšããžã§ããã£ãã¯(*5)ãªçºçŸèª¿ç¯ãä»ããçµè·¯ããèŠåºãããŸããã
ä»åãçéèèªé žã®å容äœãšããŠåå®ãããGPR109Aã¯ããã¿ãã³B矀ã®äžçš®ã§ãããã€ã¢ã·ã³(*6)ã®å容äœãšããŠç¥ãããå ç«ãççèªå°ã«ã¯ãããããã¹ã¿ã°ã©ã³ãžã³(*7)ã®åæã«é¢äžããŸãã
ãæ¬ç 究ã§ã¯ãçéèèªé žåæ§ããã€ã¢ã·ã³ãããŠã¹ã«ãããã¢ããã£ã©ãã·ãŒãæ¹åããããã¹ã¿ã°ã©ã³ãžã³ã®åæãé»å®³ããéã¹ããã€ãæ§æççè¬(NSAIDs)(*8)ãããã®æ¹åå¹æãé»å®³ããããšãæããã«ãªããŸããã
ç 究ã®èæ¯
ããã¹ã现èã¯ãäž»ã«ã¢ã¬ã«ã®ãŒåå¿ãã¢ããã£ã©ãã·ãŒã«é¢äžããå ç«çŽ°èã§ãããã¹ã现èã®è¡šé¢ã«ã¯ãIgEæäœã®å容äœ(FcεRI)ãçºçŸããŠããŸãããã®FcεRIã«IgEæäœãçµåããããã«æåãçµåããããšãããªãã¡IgEæäœãšæåãä»ããŠè€æ°ã®FcεRIãé£çµ(æ¶æ©)ããããšã§ããã¹ã现èã掻æ§åãããŸãããã¹ã现èã¯ã现èå ã«å€ãã®åæ³é¡ç²(*9)ããã¡ã掻æ§åãããšãåæ³é¡ç²ã现èå€ã«æŸåºãããè±é¡ç²ãšåŒã°ããçŸè±¡ãçãããã¹ã¿ãã³ãªã©ã®ã¢ã¬ã«ã®ãŒèªå ç©è³ªã现èå€ã«å€§éã«æŸåºããŸããããã«ãããã¢ã¬ã«ã®ãŒåå¿ãåŒãèµ·ããããŸãã
ã西山ææã®ç 究ã°ã«ãŒãã§ã¯ãé£åäžã«å«ãŸããæåããã®è žå 代è¬ç£ç©ãªã©ãå ç«å¿çã«äžãã圱é¿ã«ã€ããŠç 究ããŠããŸããä»åã西山ææãã¯ãæã¢ã¬ã«ã®ãŒäœçšã瀺ãããšãç¥ãããŠããçéèèªé žã«çç®ããŠç 究ãè¡ããŸãããè¿å¹Žãçéèèªé žããã¹ã现èã®æ©èœã調ç¯ããããšã§æã¢ã¬ã«ã®ãŒäœçšã瀺ããšããããŒã¿ãèç©ãã€ã€ãããŸããããã®èæ¯ã«ããååçãªã¡ã«ããºã ã®è©³çŽ°ã¯ãŸã ããã£ãŠããŸããã§ãããããã§æ¬ç 究ã°ã«ãŒãã¯ãããŠã¹ã»çŽ°èã»éºäŒåã¬ãã«ã®è§£æãé§äœ¿ããŠãçéèèªé žãã¢ã¬ã«ã®ãŒåå¿ã®ãšãã§ã¯ã¿ãŒçŽ°èã§ãããã¹ã现èã®æ©èœãã©ã®ããã«èª¿æŽããŠããã®ãã«ã€ããŠèª¿ã¹ãŸããã
ç 究çµæã®è©³çŽ°
ããŸããååçå šèº«æ§ã¢ããã£ã©ãã·ãŒã¢ãã«(IgEæäœãæäžãããã®åŸã«æåãæäžããããšã§ãããŠã¹ã«ã¢ããã£ã©ãã·ãŒãèªå°ãããã®)ãçšããŠãããŠã¹çäœã«å¯Ÿããçéèèªé žã®å¹æãè©äŸ¡ããŸããããããšãçéèèªé ž(é ªé žãåèé ž)ã4~6æ¥éçµå£æäžããããŠã¹ã§ã¯ãã¢ããã£ã©ãã·ãŒãææã«æå¶ãããããšãããããŸããããŸããååçç®èã¢ããã£ã©ãã·ãŒã¢ãã«(åæ§ã®ææ³ã§è¶³åºã®ç®èã«ã¢ããã£ã©ãã·ãŒãèªå°ãããã®)ãçšããå Žåã«ããçéèèªé žã®çµå£æäžã«ãããã¢ããã£ã©ãã·ãŒãæå¶ãããŸããã
次ã«ã骚é«ç±æ¥ã®ãã¹ã现èãçéèèªé žãšãšãã«å¹é€ãããã¹ã现èã«å¯Ÿããçéèèªé žã®å¹æãè©äŸ¡ããŸããããããšãçéèèªé ž(ç¹ã«é ªé žãåèé žãããããªã³é žãã€ãœåèé ž)ã§ååŠçãããã¹ã现èã§ã¯ãIgEæäœã«ããèªå°ãããè±é¡ç²ãæå¶ãããããšãããããŸããããŸããåçš®ãµã€ãã«ã€ã³(*10)ã®æŸåºããææã«æžå°ããããšãããããŸããã
ããã«ããããŒãµã€ãã¡ããªãŒæ³ããã³å®éçPCRæ³ãçšããå®éšãããçéèèªé žã¯ãFcεRIé¢é£éºäŒåã®è»¢åãé»å®³ããããšãªãã现èè¡šé¢ã®FcεRIçºçŸéãæžå°ãããããšã瀺ãããŸããã
ããã«ãçéèèªé žã®äœçšæ©æ§ã解æããã¹ããå®éçPCRæ³ãçšããŠããã¹ã现èäžã®è茞éã¿ã³ãã¯è³ªãå容äœã調ã¹ãŸãããåå®ããããã®ã®äžãããåçš®é»å®³å€ãéºäŒåæè¡ãçšããå®éšã«ãããçéèèªé žã®å容äœãšããŠGã¿ã³ãã¯è³ªå ±åœ¹åå容äœGPR109Aãçµã蟌ãŸããŸããã
çéèèªé žã瀺ãæççäœçšã«ã¯ããã¹ãã³è±ã¢ã»ãã«åé µçŽ é»å®³å€(HDACi)(*11)ãšããŠã®æŽ»æ§ãé¢äžããããšãå ±åãããŠããŸããããã§ãHDACiã®äžçš®ããªã³ã¹ã¿ãã³Aã§ãã¹ã现èãåŠçããè±é¡ç²ã®çšåºŠããµã€ãã«ã€ã³æŸåºéãFcεRIã®mRNAéãããã³ãã¹ã现èè¡šé¢ã«çºçŸããFcεRIéã調ã¹ããšãããçéèèªé žã§åŠçããå Žåãšåæ§ã®çµæãåŸãããŸããã
以äžã®çµæãããçéèèªé žã®äœçšæ©æ§ã«ã¯ã现èè¡šé¢ã«çºçŸããGã¿ã³ãã¯è³ªå ±åœ¹åå容äœGPR109Aãä»ããçµè·¯ãšãHDACiãšããŠå ç«é¢é£éºäŒåã®çºçŸããšããžã§ããã£ãã¯ã«èª¿ç¯ããçµè·¯ãããã2ã€ã®çµè·¯ãé¢äžããããšã瀺ãããŸããã
ãä»åçéèèªé žã®å容äœãšããŠåå®ãããGPR109Aã¯ããã³ãã³é ž(ãã€ã¢ã·ã³ã»ãã¿ãã³B3ã®äžçš®)ã®å容äœãšããŠç¥ããããã³ãã³é žãšçµåããããšã§ããã¹ã¿ã°ã©ã³ãžã³ã®ç£çãä¿é²ããŸããããã§ãããã¹ã¿ã°ã©ã³ãžã³ã®åæãé»å®³ããNSAIDs(ã¢ã»ãã«ãµãªãã«é žãã€ã³ãã¡ã¿ã·ã³)ã§ãã¹ã现èãåŠçãããšãããçéèèªé žã«ããè±é¡ç²æå¶å¹æãé»å®³ãããŸããããŸããååçç®èã¢ããã£ã©ãã·ãŒã¢ãã«ã«ãããŠããã³ãã³é žã®å¹æãè©äŸ¡ãããšããããã³ãã³é žã¯ã¢ããã£ã©ãã·ãŒãææã«æå¶ãããã®å¹æã¯NSAIDsã«ãã£ãŠæã¡æ¶ãããŸãããããã«ãååçå šèº«æ§ã¢ããã£ã©ãã·ãŒã¢ãã«ã«ããããçéèèªé žã®ã¢ããã£ã©ãã·ãŒæå¶å¹æããNSAIDsã«ãã£ãŠé»å®³ãããŸãããå ããŠãNSAIDsã®äœçšã«é¢ãã詳现ãªè§£æã«ãããããã¹ã¿ã°ã©ã³ãžã³ã®ãã¡ãç¹ã«ããã¹ã¿ã°ã©ã³ãžã³E2ããã¹ã现èã®æŽ»æ§åãæããããšãè€æ°ããããã¹ã¿ã°ã©ã³ãžã³E2å容äœã®ãã¡EP3ãã¢ããã£ã©ãã·ãŒã®æå¶ã«é¢ããããšãçéèèªé žããã³ãã³é žã®å¹æãEP3é»å®³å€ã«ãã£ãŠæžåŒ±åããããšãªã©ã瀺åãããŠããŸãã
ãããäžé£ã®çµæãããçéèèªé žã¯ãå容äœGPR109Aãä»ããŠããã¹ã¿ã°ã©ã³ãžã³ã®ç£çãä¿é²ããããšã§ããã¹ã现èã®æŽ»æ§åãæå¶ããã¢ããã£ã©ãã·ãŒã®æå¶ã«ã¯ãããããšã瀺ãããŸããã
ãæ¬ç 究ææã«ã€ããŠã西山ææã¯ãæ¬ç 究ã¯ãæ¥æ¬äººã®2人ã«1人ãäœããã®ã¢ã¬ã«ã®ãŒãæã€ãšèšãããã»ã©èº«è¿ãªçŸæ£ã§ããã¢ã¬ã«ã®ãŒã«å¯Ÿãããé£ç©ç¹ç¶ã®æå¹æ§ãæããã«ãããã®ã§ããNSAIDsã¯ãåæ¯ãççæ§è žçŸæ£ãªã©ã®äžéšã®ã¢ã¬ã«ã®ãŒãçççŸæ£ã«ãããŠææªåãããããããšãç¥ãããŠãããä»åã®ç¥èŠã¯ããã®ç¹ã«ãåã蟌ãã ãã®ã§ããããã«ãã¢ã¬ã«ã®ãŒã«å¯Ÿãããã¿ãã³ã®åœ±é¿ã確èªãããŸããããããã¹ã¿ã°ã©ã³ãžã³ã®åæã«ã¯å€äŸ¡äžé£œåèèªé žãé¢ä¿ããããšãåå²éèèªé žã¯çŽè±ãªã©ã«ãå«ãŸããŠããããšãèžãŸããŠããé£äºãæ¥åžžç掻ãšé¢é£ã®æ·±ãããŒããšãªã£ããšæããŸãããšèªã£ãŠããŸãã
çšèªèª¬æ
*1 çéèèªé ž
äž»ã«è žå 现èã«ãã£ãŠæ°Žæº¶æ§é£ç©ç¹ç¶ããªãªãŽç³ã代è¬ãããããšã§çæããææ©é žã®ç·ç§°ãè žç®¡ããåžåãããŠè žäžç®çŽ°èã®ãšãã«ã®ãŒæºãšããŠå©çšãããã»ããè¡æµã«ä¹ã£ãŠå šèº«ã«éã°ããèèãçèã§ã®ä»£è¬ã«å©çšããããçéèèªé žã«ã¯ãè žå ãåŒ±é žæ§ã«ä¿ã¡ãæ害ãªèã®å¢æ®ãé»å®³ããããšã§ãè žå ç°å¢ãè¯å¥œã«ä¿ã€æ©èœãããã
*2 ãã¹ã现è
ç®èãç²èãªã©äž»ã«å€çãšæ¥ããçµç¹ã«å€ãååžããæ¬æ¥ã¯å¯çè«ã现èãªã©ã®ææé²åŸ¡ã«æ©èœããå ç«çŽ°èãè¥æºçŽ°èãšãåŒã°ããã
*3 IgEæäœå
ç«ã°ãããªã³Eããæ§æãããæäœãç¹å®ã®ã¢ã¬ã«ã²ã³(æå)ãäœå ã«äŸµå ¥ããéã«ç£çãããå³æçãªã¢ã¬ã«ã®ãŒåå¿ãåŒãèµ·ããã
*4 Gã¿ã³ãã¯è³ªå ±åœ¹åå容äœ
ç¥çµäŒéç©è³ªããã«ã¢ã³ãªã©ãèªèããã现èèäžã®å容äœãGã¿ã³ãã¯è³ªã®æŽ»æ§åãä»ããŠã现èå€ã®æ å ±ã现èå ã«äŒããã¯ãããããã€ã
*5 ãšããžã§ããã£ãã¯
DNAã®å¡©åºé åãå€ããããšãªããDNAããã¹ãã³ã®ååŠä¿®é£Ÿ(ã¡ãã«åãã¢ã»ãã«åãªã©)ãä»ããŠéºäŒåã®çºçŸãå¶åŸ¡ããã
*6 ãã€ã¢ã·ã³
ãã¿ãã³B矀ã®äžçš®(ãã¿ãã³B3)ã§ããããã³ãã³é žãšãã³ãã³ã¢ããã®ç·ç§°ã
*7 ããã¹ã¿ã°ã©ã³ãžã³
åºè³ªãšãªãã¢ã©ããã³é žãããé µçŽ ã§ããã·ã¯ããªãã·ã²ããŒãŒ(COX)ã«ãã£ãŠçæãããçç掻æ§ç©è³ªãPGE2ãPGD2ãªã©ã®çš®é¡ããããããããã«ç°ãªãæ©èœããã€ã
*8 éã¹ããã€ãæ§æççè¬(NSAIDs, Non-steroidal anti-inflammatory drugs)
ã¢ã©ããã³é žã«ã¹ã±ãŒãã«ãããŠCOXãé»å®³ããããã¹ã¿ã°ã©ã³ãžã³ã®åæãæå¶ããããšã§ãé®çã»è§£ç±ã»æççäœçšã瀺ããã¢ã»ãã«ãµãªãã«é ž(ã¢ã¹ããªã³)ãã€ã³ãã¡ã¿ã·ã³ãªã©ãããã
*9 åæ³é¡ç²
åæ³çŽ°èå ã«ã¿ãããå°ããªé¡ç²ãé¡ç²å éšã«ã¯åæ³ç©ãèããããŠããã
*10 ãµã€ãã«ã€ã³
现èéã®æ å ±äŒéã«ã¯ãããã¿ã³ãã¯è³ªãã€ã³ã¿ãŒãã€ãã³(IL)ãè «çå£æ»å å(TNF)ãªã©ãããã
*11 ãã¹ãã³è±ã¢ã»ãã«åé µçŽ é»å®³å€(HDACi, Histone deacetylase inhibitor)
äžè¬ã«ãã¹ãã³ãã¢ã»ãã«åããããšã転åå åãæè²äœã«è¿ã¥ãããããªãã転åãä¿é²ããããHDACiã¯ãã¹ãã³ã®è±ã¢ã»ãã«åãé»å®³ããããããã¹ãã³ã®ã¢ã»ãã«åãã²ããŠã¯è»¢åãä¿é²ããã